169328 ⎘
Investigating or analysing materials by specific methods not covered by groups -; Biological material, e.g. blood, urine ; Haemocytometers; Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
TREATING PULMONARY HYPERTENSION BASED ON NOVEL BIOMARKER
#2BIOMARKERS FOR DIAGNOSING EQUINE ASTHMA
#3PULMONARY ARTERIAL HYPERTENSION PATIENT SELECTION METHOD AND BIOMARKER
#4METHODS RELATING TO IMPAIRED RESPIRATORY HEALTH THERAPEUTICS
#5MONITORING INFLAMMATION STATUS
#6COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION
#7BIOMARKERS FOR THE TREATMENT OF INTERSTITIAL LUNG DISEASE
#8PROTEIN CORONA BIOMARKER ANALYSIS
#9Method for diagnosis of lung disease based on antibodies for microbial-derived vesicles
#10ISOLATED HUMAN LUNG PROGENITOR CELLS AND USES THEREOF
#11COMPOSITIONS AND TREATMENTS FOR CORONAVIRUS INFECTIONS
#12DIAGNOSIS OF ACUTE AND CHRONIC LUNG DISEASES BY QUANTIFYING SPINK1 LEVEL
#13METHODS AND COMPOSITIONS FOR TREATING PULMONARY ALVEOLAR PROTEINOSIS RELATED TO MARS MUTATIONS
#14COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRONCHIOLITIS OBLITERANS
#15A Point of Care Device, Method and Kit Involving Club Cell Protein 16 as a Marker for Silicosis
#16Pulmonary hypertension biomarker
#17BIOMARKER COMBINATIONS IN EX VIVO LUNG PERFUSION (EVLP) PERFUSATE
#18Isolated human lung progenitor cells and uses thereof
#19Compositions and methods for detection and treatment of coronavirus infection
#20Methods of treating chronic disorders with complement inhibitors
#21Pulse Stable Tracer Methods for Detection of Short-Chain Fatty Acids
#22Methods of treating chronic disorders with complement inhibitors
#23Image selection suggestions
#24PULMONARY HYPERTENSION BIOMARKER
#25Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of COPD
#26Isolated human lung progenitor cells and uses thereof
#27EPHA3 ANTIBODIES FOR THE TREATMENT OF PULMONARY FIBROSIS
#28METHODS OF TREATING CHRONIC DISORDERS WITH COMPLEMENT INHIBITORS
#29Method of treating asthma using an IL-13 antibody
#30Methods of Treating Subjects having Severe and/or Persistent Asthma
#31Methods of using antibodies to determine periostin levels in a sample
#32NOVEL ASSAY TO DETECT HUMAN PERIOSTIN
#33Isolated human lung progenitor cells and uses thereof
#34ANTI-HIMF ANTIBODIES TO TREAT LUNG DISEASES
#35BARD1 isoforms in lung and colorectal cancer and use thereof
#36Therapeutic agent for emphysema and COPD
#37PULMONARY HYPERTENSION BIOMARKER
#38Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin II
#39Monoclonal antibodies which bind human periostin
#40Methods of Treating Subjects having Severe and/or Persistent Asthma
#41Prognosis of chronic obstructive pulmonary disease (COPD) and treament for COPD
#42Methods and compositions for assessing lung grafts
#43Chronic obstructive pulmonary disease (COPD) biomarkers and uses thereof
#44Method for determining acute respiratory distress syndrome (ARDS) related biomarkers, a method to monitor the development and treatment of ARDS in a patient
#45Methods for diagnosing pulmonary hypertension
#46DETECTION AND TREATMENT OF NON-DERMAL FIBROSIS
#47ARMET AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
#48Systemic genotoxicity as blood marker for allergic inflammation
#49Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
#50Method for Dosage Adjustment of Drugs that Prevent Elastic Fiber Breakdown
#51Diagnosis and risk stratification by determining the marker CT-proADM
#52Methods of treating chronic disorders with complement inhibitors
#53BIOMARKER FOR CHRONIC INFLAMMATORY LUNG DISEASES
#54FORENSIC METHOD
#55Isolated human lung progenitor cells and uses thereof
#56LTBP2 AS A BIOMARKER FOR LUNG INJURY
#57Method for Determining Lung Injury Using Desmosine and Isodesmosine as Biomarkers
#58Therapeutic agent for emphysema and COPD
#59Diagnosis and treatments relating to TH2 inhibition
#60Diagnosis and treatments relating to TH2 inhibition
#61ASC as a marker for chronic obstructive pulmonary disease (COPD)
#62Identification and Treatment of Aggressive Lung Cancer Tumors
#63METHOD FOR DIAGNOSING ACUTE LUNG INJURY
#64USE OF SPECIFIC GENES FOR THE PROGNOSIS OF LUNG CANCER AND THE CORRESPONDING PROGNOSIS METHOD
#65USE OF SPECIFIC GENES OR THEIR ENCODED PROTEINS FOR A PROGNOSIS METHOD OF CLASSIFIED LUNG CANCER
#66MARKERS OF PRIMARY GRAFT DYSFUNCTION
#67P-SELECTIN ASSOCIATED WITH EOSINOPHILS AS A MARKER FOR ASTHMA AND CORRELATING WITH B-1 INTEGRIN ACTIVATION
#68METHOD FOR DISCRIMINATING BETWEEN EARLY AND ADVANCED STAGE LUNG CARCINOMA
#69Method for screening for a therapeutic agent for idiopathic interstitial pneumonia
#70Lung Cancer Tests
#71Biomarkers associated with autoimmune diseases of the lung
#72Compositions and methods for detecting, diagnosing, and treating cancer
#73Diagnostic marker for lung cancer comprising HPαR as active ingredient
#74BARD1 isoforms in lung and colorectal cancer and use thereof
#75DIAGNOSIS AND RISK STRATIFICATION OF INFECTIONS AND CHRONIC DISEASES OF THE RESPIRATORY TRACT AND LUNGS BY MEANS OF PROVASOPRESSIN, PARTICULARLY COPEPTIN OR NEUROPHYSIN II
#76DIAGNOSIS AND TREATMENTS RELATING TO TH2 INHIBITION
#77Semi-Invasive Method for Characterizing Lung Injury
#78Immunoassay reagent for KL-6 assay
#79Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation
#80Identification and Treatment of Aggressive Lung Cancer Tumors
#81Detection and treatment of non-dermal fibrosis
#82MMP activation peptide detection in biological samples
#83P-SELECTIN ASSOCIATED WITH EOSINOPHILS AS A MARKER FOR ASTHMA AND CORRELATING WITH B-1 INTEGRIN ACTIVATION
#84METHOD OF DIAGNOSIS
#85Method for detection of idiopathic interstitial pneumonia
#86METHODS AND COMPOSITIONS FOR IDENTIFYING LUNG CANCER OR A HUMORAL IMMUNE RESPONSE AGAINST LUNG CANCER
#87FLUORESCENT TWO-HYBRID (F2H) ASSAY FOR DIRECT VISUALIZATION OF PROTEIN INTERACTIONS IN LIVING CELLS
#88SURFACTANT PROTEINS B AND D FOR DIFFERENTIAL DIAGNOSIS OF DYSPNEA
#89Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
#90Method for identifying smoker or ex-smoker at risk of chronic obstructive pulmonary disease
#91Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin II
#92Diagnosis and risk stratification by determining the marker CT-proADM
#93Anti-HIMF antibodies to treat lung diseases
#94Method of stabilizing pulmonary surfactant protein
#95Methods for differentiation between cardiac and pulmonary causes of chronic dyspnea
#96P-Selectin associated with Eosinophils as a marker for asthma and correlating with B-1 integrin activation
#97Composition for prevention, treatment, and diagnosis of chronic obstructive pulmonary disease (COPD)
#98Methods of diagnosing tumors using the G-protein coupled receptor (GPCR), RAI-3
#99TAT-036 and methods of assessing and treating cancer
#100Elastin peptide fingerprints and analysis methods for MMP12 related to COPD
#101Method for detecting diseases that are associated with defects of cystic fibrosis transmembrane conductance regulator (CFTR) protein
#102Method for assessment of cystic lung fibrosis